Thailand approved pilot study on treatment of COVID-19 with Andrographis paniculata

• Thailand's Initiative: Approved a pilot study for Andrographis paniculata as a treatment for early COVID-19 symptoms.

• Study Design: Voluntary participation for individuals aged 18-60 in state-owned hospitals, receiving the herb within 72 hours of symptom onset.

• Phase One Results: Patients received 60 mg or 100 mg capsules of Andrographis extract. Results showed significant improvement in cough and symptom severity, with negative COVID-19 PCR tests in all subjects within three weeks.

• Phase Two: Involved 60 subjects receiving either Andrographis or a placebo, focusing on the herb's effectiveness and safety.

• Global Implications: Annie Eng of HP Ingredients highlights Thailand's leadership in botanical immune optimization, supporting the use of Andrographis in clinical trials.

• Ongoing Trials: Two human clinical trials are evaluating HP Ingredients’ Andrographis paniculata product, ParActin. One trial is assessing its effects on frontline healthcare workers in Chile, while another is a randomized study comparing ParActin and MaquiCare maqui berry extract for respiratory tract challenges.

• Research Significance: Eng emphasizes the importance of continual botanical research for health and wellness, suggesting a steady stream of positive studies will enhance the role of botanicals in healthcare.

Thailand's pioneering study marks a significant step in exploring Andrographis Paniculata's role in managing COVID-19, potentially offering a safe, effective, and affordable treatment alternative.

Source: https://www.nutritionaloutlook.com/view/thailand-approved-pilot-study-on-treatment-of-covid-19-with-andrographis-paniculata